Avero Diagnostics launches test for early-stage melanoma progression with AMLo Biosciences Avero Diagnostics (Bellingham (Washington) and Irving (Texas), USA) today announced the U.S. launch of AMBLor®, for identification of early-stage melanomas at low risk of...
We are delighted to announce that our very own CSO, Professor Penny Lovat, has been shortlisted for Woman Entrepreneur of the Year at the Cancer Research Horizons Innovation and Entrepreneurship Awards 2022 #IEAwards22.These prestigious annual awards recognise the...
In a busy October, AMLO's commercial team had booths at the recent Focus on Melanoma 2022 meeting in London and at the Society for Melanoma Resesarch (SMR) Congress in Edinburgh. The Melanoma Focus meeting was very well attended. Marketing Director Jane Meaney and UK...
Today NICE published their Advice on “AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas”. This formal external review and publication is a significant step in getting AMBLor® adopted into clinical care pathways in the UK. It follows on from...
Today NICE published their Advice on “AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas”. This formal external review and publication is a significant step in getting AMBLor® adopted into clinical care pathways in the UK. It follows on from...
AMLo Biosciences Ltd (AMLo), an innovative medical device company spun out of Newcastle University specialising in the early detection of skin cancers, is pleased to announce it has secured significant further investment totalling £2.45m. At present all early stage...
AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534
Trading address (Visitors and Deliveries): Office 9, The Biosphere, Drayman's Way, Newcastle Helix, Newcastle upon Tyne, NE4 5BX ///wider.admire.guard
Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom
VAT # 285288950
Sign up for our newsletter